Patient Access

Biosimilars are poised to disrupt the drug chain in 2023. What do brokers and plan sponsors need to know?

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?  

With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.

Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

Generic versions of brand name medications are not all the same. Understanding their differences and their implications on MAC pricing is critical for choosing the most cost-effective PBM.

Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent? 

Adopting these three approaches can help manufacturers to build a more effective affordability program. 

Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.

Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?

While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.

The price of drugs on your pharmacy benefits plan can vary dramatically, depending on its type.